PreveCeutical Medical Inc (PRVCF)

[NetworkNewsWire]

PRVCF CEO, Chief Research Officer Discuss Company’s Response to Opioid Epidemic

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was featured in an interview today by Proactive Investors. Chairman and CEO Stephen Van Deventer and chief research officer Dr. Harry Parekh discussed the company’s four programs: Sol-Gel, Nature Identical™, Dual Gene Therapy and Engineering Peptide Therapeutics. Among other topics, they discuss the rising rate of opioid overdoses and addiction, which the company’s planning to tackle utilizing its proprietary linker technology to engineer peptide therapeutics. “What’s key about the technology is you cannot create tolerance to this treatment and you cannot overdose as well,” PreveCeutical chairman and CEO Stephen Van Deventer stated in the interview. Additionally, they noted the company’s recent appointment of Dr. Maher Khaled to the position of director of international operations as a “perfect fit” for PreveCeutical’s programs moving forward.

To view the full video, visit http://nnw.fm/1cMts

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com.